Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Go To Market Consulting and Debiopharm Collaborate

Published: Friday, September 27, 2013
Last Updated: Friday, September 27, 2013
Bookmark and Share
Collaboration to identify early stage in-licensing opportunities on the US West Coast.

Go To Market Consulting Inc. (Go To Market) and Debiopharm Group™ (Debiopharm) have entered into an alliance to identify and scout West Coast companies, research institutes and/or individual investigators with in-licensing opportunities, including new compounds, products and/or technologies in oncology, auto-immune, infectious disease and metabolic conditions.

Go To Market will collaborate with Debiopharm’s existing in-house scouting team for first in-class opportunities for small molecule, antibody and peptide based product candidates.

In recognition of the depth and breadth of life science innovation in the West and in particular, the San Francisco Bay area, known for its culture of innovation, Debiopharm has selected Go To Market to strengthen its local activity in the region.

Go To Market will work with Debiopharm’s experienced scouting team to further increase the company’s accessibility to in-licensing opportunities.

David Deperthes, Vice President, Business Development & Licensing at Debiopharm said: “We have selected Go To Market because of their strength and understanding in the life sciences product development area. Their successful presence on the West Coast is a major asset to our search for new molecules. With this partnership we are deepening our commitment to finding the most promising drugs to develop for patients.”

Maria Chiam, Founder of Go To Market added: “the West Coast is a rich area in science innovation. Debiopharm’s track record of investing into and collaborating with early stage biopharmaceutical programs make it a choice partner for researchers and organizations wanting to move their preclinical programs into clinical development. Go To Market Consulting is delighted to work with Debiopharm to bring next generation therapeutics and diagnostic and personalized medicine initiatives to the market.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

JCA and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award
The ‘JCA-Mauvernay Award 2015’ is awarded to Doctors Yutaka Kondo and Junko Takita.
Saturday, October 10, 2015
Debiopharm and Solid Biosciences Announces Collaboration
Debiopharm to start pre-clinical animal studies in Duchenne Muscular Dystrophy with Solid Biosciences.
Thursday, September 10, 2015
Debiopharm Acquires FibroTrap Sample Processing Technology from Spinomix
FibroTrap improves sensitivity and shortens time taken from sample collection to results.
Saturday, June 20, 2015
Debiopharm Announces Phase III Positive Results for Triptorelin 6-month Formulation
Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting or reversing progression of clinical signs of puberty and slowing down of accelerated bone maturation in children with CPP.
Friday, May 22, 2015
Debiopharm Initiates Clinical Phase II Study to Evaluate Debio 1450
One year after the initiation of Phase I, Debiopharm has announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID.
Friday, May 01, 2015
Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
Company presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347.
Tuesday, April 21, 2015
Debiopharm Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450
Debio 1450 - A highly potent anti-infective agent selectively active against Staphylococcus species.
Wednesday, October 15, 2014
Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada
Trelstar® one-, three-, and six-month dosing options now available.
Wednesday, October 08, 2014
Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Debiopharm, Yale University Extend Collaboration
New license and research agreement regarding the discovery of MIF inhibitors.
Wednesday, May 07, 2014
Curis and Debiopharm Report Preclinical Data for Debio 0932
Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.
Wednesday, April 09, 2014
Debiopharm to Acquire Products or Companies
Company to expand activities at manufacturing facility in Martigny (Valais, Switzerland).
Saturday, March 08, 2014
Immunexpress Closes $6M Financing Round led by Debiopharm
Funding to advance development of the Immunexpress SeptiCyte® technology.
Thursday, March 06, 2014
Debiopharm to Acquire Affinium’s Antibiotic Clinical Assets and Platform
Company acquire clinical and preclinical assets to identify and develop targeted antibiotics.
Wednesday, February 12, 2014
Debiopharm Announces Completion of Recruitment for Phase III Clinical Study in CPP
Completion of recruitment and results are expected in Q4 2014.
Monday, January 20, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos